Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 7 versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 7 versus TRAVASOL 5 5 IN PLASTIC CONTAINER.
AMINOSYN II 7% vs TRAVASOL 5.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
Travasol 5.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting metabolic functions in parenteral nutrition.
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
500 mL of 5.5% amino acid solution intravenously over 2-4 hours daily, titrated to nitrogen balance and metabolic tolerance.
None Documented
None Documented
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Not applicable as individual amino acids have variable half-lives (minutes to hours). TRAVASOL is a mixture; the clinical context is continuous infusion to maintain plasma levels.
Renal as amino acids and metabolites; negligible biliary/fecal.
Amino acids in TRAVASOL 5.5% are metabolized and nitrogen waste is excreted primarily via renal elimination (as urea, >90% of nitrogen). Fecal elimination is negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution